632 related articles for article (PubMed ID: 17416287)
1. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
4. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
5. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
6. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
Himbergen TM; van Tits LJ; Voorbij HA; de Graaf J; Stalenhoef AF; Roest M
J Intern Med; 2005 Nov; 258(5):442-9. PubMed ID: 16238680
[TBL] [Abstract][Full Text] [Related]
7. Main determinants of PON1 activity in hemodialysis patients.
Ribeiro S; do Sameiro Faria M; Mascarenhas-Melo F; Freitas I; Mendonça MI; Nascimento H; Rocha-Pereira P; Miranda V; Mendonça D; Quintanilha A; Belo L; Costa E; Reis F; Santos-Silva A
Am J Nephrol; 2012; 36(4):317-23. PubMed ID: 23007074
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
9. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
Dallongeville J; Fruchart JC; Pfister P; Bard JM
J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
[TBL] [Abstract][Full Text] [Related]
10. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.
Cherki M; Berrougui H; Isabelle M; Cloutier M; Koumbadinga GA; Khalil A
Exp Gerontol; 2007 Aug; 42(8):815-24. PubMed ID: 17532162
[TBL] [Abstract][Full Text] [Related]
11. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians.
Campo S; Sardo MA; Trimarchi G; Bonaiuto M; Fontana L; Castaldo M; Bonaiuto A; Saitta C; Bitto A; Manduca B; Riggio S; Saitta A
Exp Gerontol; 2004 Jul; 39(7):1089-94. PubMed ID: 15236768
[TBL] [Abstract][Full Text] [Related]
12. Human paraoxonase gene polymorphisms and coronary artery disease risk.
Mendonça MI; Dos Reis RP; Freitas AI; Sousa AC; Pereira A; Faria P; Gomes S; Silva B; Santos N; Serrão M; Ornelas I; Freitas S; Araújo JJ; Brehm A; Cardoso AA
Rev Port Cardiol; 2008 Dec; 27(12):1539-55. PubMed ID: 19280995
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
Samuelsson O; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Alaupovic P
Am J Kidney Dis; 2002 Jan; 39(1):67-75. PubMed ID: 11774104
[TBL] [Abstract][Full Text] [Related]
14. Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease.
Fu R; Sun YM; Su Y; Wu Y; Luan Y
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):982-3. PubMed ID: 18430057
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
Hailer S; Pogarell O; Keller C; Wolfram G
Arzneimittelforschung; 1996 Sep; 46(9):879-83. PubMed ID: 8876936
[TBL] [Abstract][Full Text] [Related]
16. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
Mirdamadi HZ; Sztanek F; Derdak Z; Seres I; Harangi M; Paragh G
Br J Clin Pharmacol; 2008 Sep; 66(3):366-74. PubMed ID: 18492126
[TBL] [Abstract][Full Text] [Related]
17. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P
Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy.
Kovács TJ; Harris S; Vas TK; Seres I; Short CD; Wittmann IK; Paragh G; Mackness MI; Mackness B; Durrington PN; Nagy JM; Brenchley PE
J Nephrol; 2006; 19(6):732-8. PubMed ID: 17173245
[TBL] [Abstract][Full Text] [Related]
19. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects.
Sirivarasai J; Kaojarern S; Yoovathaworn K; Sura T
Chem Biol Interact; 2007 Jul; 168(3):184-92. PubMed ID: 17532308
[TBL] [Abstract][Full Text] [Related]
20. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome.
Koubaa N; Nakbi A; Hammami S; Attia N; Mehri S; Ben Hamda K; Ben Farhat M; Miled A; Hammami M
Clin Biochem; 2009 Jun; 42(9):771-6. PubMed ID: 19269283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
